MedTrace Logo

Binding of Lu AG06466 in the Brain in Healthy Men

NCT04419636 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-02-24

No results posted yet for this study

Summary

A study to learn how Lu AG06466 and one of its break down products binds in the brain after single and repeated dosing

Conditions

  • Healthy

Interventions

DRUG

Lu AG06466

capsules, orally

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-29
Primary Completion
2021-02-09
Completion
2021-02-16

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04419636 on ClinicalTrials.gov